1
|
Khurm M, Guo Y, Wu Q, Zhang X, Ghori MU, Rasool MF, Imran I, Saqib F, Wahid M, Guo Z. Conocarpus lancifolius (Combretaceae): Pharmacological Effects, LC-ESI-MS/MS Profiling and In Silico Attributes. Metabolites 2023; 13:794. [PMID: 37512501 PMCID: PMC10385132 DOI: 10.3390/metabo13070794] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 06/17/2023] [Accepted: 06/19/2023] [Indexed: 07/30/2023] Open
Abstract
In folklore medicine, Conocarpus lancifolius is used to treat various illnesses. The main objective of this study was a comprehensive investigation of Conocarpus lancifolius leaf aqueous extract (CLAE) for its antioxidant, cardioprotective, anxiolytic, antidepressant and memory-enhancing capabilities by using different in vitro, in vivo and in silico models. The in vitro experimentation revealed that CLAE consumed an ample amount of total phenolics (67.70 ± 0.15 µg GAE/mg) and flavonoids (47.54 ± 0.45 µg QE/mg) with stronger antiradical effects through DPPH (IC50 = 16.66 ± 0.42 µg/mL), TAC (77.33 ± 0.41 µg AAE/mg) and TRP (79.11 ± 0.67 µg GAE/mg) assays. The extract also displayed suitable acetylcholinesterase (AChE) inhibitory (IC50 = 110.13 ± 1.71 µg/mL) activity through a modified Ellman's method. The toxicology examination presented no mortality or any signs of clinical toxicity in both single-dose and repeated-dose tests. In line with the cardioprotective study, the pretreatment of CLAE was found to be effective in relieving the isoproterenol (ISO)-induced myocardial injury in rats by normalizing the heart weight index, serum cardiac biomarkers, lipid profile and various histopathological variations. In the noise-stress-induced model for behavior attributes, the results demonstrated that CLAE has the tendency to increase the time spent in the central zone and elevated open arms in the open field and elevated plus maze tests (examined for anxiety assessment), reduced periods of immobility in the forced swimming test (for depression) and improved recognition and working memory in the novel object recognition and Morris water maze tests, respectively. Moreover, the LC-ESI-MS/MS profiling predicted 53 phytocompounds in CLAE. The drug-likeness and ADMET analysis exhibited that the majority of the identified compounds have reasonable physicochemical and pharmacokinetic profiles. The co-expression of molecular docking and network analysis indicated that top-ranked CLAE phytoconstituents act efficiently against the key proteins and target multiple signaling pathways to exert its cardiovascular-protectant, anxiolytic, antidepressant and memory-enhancing activity. Hence, this artifact illustrates that the observed biological properties of CLAE elucidate its significance as a sustainable source of bioactive phytochemicals, which appears to be advantageous for pursuing further studies for the development of new therapeutic agents of desired interest.
Collapse
Affiliation(s)
- Muhammad Khurm
- School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China
| | - Yuting Guo
- School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China
| | - Qingqing Wu
- School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China
| | - Xinxin Zhang
- School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China
| | - Muhammad Umer Ghori
- Department of Bioinformatics and Biotechnology, Government College University, Faisalabad 38000, Pakistan
| | - Muhammad Fawad Rasool
- Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan
| | - Imran Imran
- Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan
| | - Fatima Saqib
- Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan
| | - Muqeet Wahid
- Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan
| | - Zengjun Guo
- School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China
| |
Collapse
|
2
|
Parvez M, Hussain F, Khan M. Crude extract from Euphorbia prostrata extended curative period of glibenclemide in alloxan-induced diabetic rats. JOURNAL OF COMPLEMENTARY & INTEGRATIVE MEDICINE 2023; 20:372-378. [PMID: 36662647 DOI: 10.1515/jcim-2022-0315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Accepted: 01/03/2023] [Indexed: 06/16/2023]
Abstract
OBJECTIVES Euphorbia prostrata is traditionally used alongside antidiabetic agents to manage diabetes. Bioactive ingredients of medicinal herbs may alter the overall pharmacokinetics of antidiabetic agents. METHODS We assessed hypoglycemic activities of ethanolic plant extract (EPE) singly and its effects on antidiabetic properties of gliclazide, glibenclemide and metformin in allaxonized rats. Varying concentrations of EPE (250 and 500 mg/kg) with or without metformin (10 mg/kg), glibenclemide (2 mg/kg) and gliclazide (5 mg/kg) were orally administered to evaluate herb-drug interaction. RESULTS The levels of blood glucose declined significantly after treatment with metformin, glibenclemide and gliclazide singly (p<0.01) or concomitantly with EPE (p<0.001). Concentration dependent mild to moderate reduction (5.2 and 10.0%) was registered in blood glucose for 250 and 500 mg/kg of EPE respectively. The overall reduction in blood glucose due to combined treatment with EPE and standard agents was additive. On the other hand, synergistic herb-drug interaction was registered for insulin levels in rats that received glibenclamide and gliclazide alongside EPE. Extract with metformin had antagonistic insulin outcome. Regarding the duration of hypoglycemic activities, periodical changes were similar in case of glibenclamide and gliclazide separately or in combination with EPE. However, in case of metformin with extract, the blood glucose continued to decline for 14 h and retained at 15.0% below the baseline values even after 24 h of treatment. CONCLUSIONS In conclusion, the extract itself had weak hypoglycemic effects but prolonged the therapeutic duration of metformin to more than 24 h when administered combinedly.
Collapse
Affiliation(s)
- Mohammad Parvez
- Institute of Biological Sciences, Sarhad University of Science and Information Technology (SUIT), Peshawar, Pakistan
| | - Farrukh Hussain
- Institute of Biological Sciences, Sarhad University of Science and Information Technology (SUIT), Peshawar, Pakistan
| | - Murad Khan
- Environmental and Conservation Sciences, University of Swat, Swat, Pakistan
| |
Collapse
|
3
|
Song SY, Park JH, Park SJ, Kang IC, Yoo HS. Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer. Integr Cancer Ther 2022; 21:15347354221144311. [PMID: 36565160 PMCID: PMC9793066 DOI: 10.1177/15347354221144311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
In epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), acquired resistance to EGFR tyrosine kinase inhibitors (TKI) leads to disease progression. Strategies to overcome the resistance are required in treatment for advanced lung cancer. In this study, we investigated the therapeutic effect of afatinib and HangAmDan-B1 (HAD-B1) co-administration in gefitinib-resistant NSCLC using HCC827-GR, NSCLC cell line with gefitinib resistance, and the HCC827-GR cell implanted mouse model. HAD-B1 consists of 4 herbs, Panax notoginseng Radix, Cordyceps militaris, Panax ginseng C. A. Mey, and Boswellia carteri Birdwood, and has been reported to be effective in patients with advanced lung cancer in clinical practice. Our findings demonstrated that HAD-B1 combined with afatinib markedly inhibited cell proliferation and induced apoptosis compared to afatinib monotherapy and HAD-B1 monotherapy. Inhibition of HCC827-GR cell proliferation by HAD-B1 occurred through MET amplification and reduced phosphorylation, and the synergistic effect of afatinib and HAD-B1 induced cell cycle arrest and apoptosis in HCC827-GR cells via the downregulation of ERK and mTOR signaling pathways. In hematology and biochemistry tests, HAD-B1 alleviated the toxicity of tumor. In conclusion, HAD-B1 combined with afatinib would be a promising therapeutic strategy for NSCLC with EGFR-TKI resistance.
Collapse
Affiliation(s)
- Si Yeon Song
- Daejeon Korean Medicine Hospital of
Daejeon University, Daejeon, Republic of Korea
| | - Ji Hye Park
- Seoul Korean Medicine Hospital of
Daejeon University, Seoul, Republic of Korea
| | - So-Jung Park
- Korean Medicine Hospital of Pusan
National University, Yangsan-si, Republic of Korea
| | - In-Cheol Kang
- Innopharmascreen, Inc., Incheon,
Republic of Korea,Hoseo University, Asan, Republic of
Korea
| | - Hwa-Seung Yoo
- Seoul Korean Medicine Hospital of
Daejeon University, Seoul, Republic of Korea,Hwa-Seung Yoo, East-West Cancer Center,
Seoul Korean Medicine Hospital of Daejeon University Seoul, 1136 Dunsan-dong,
Seo-gu, Daejeon 302-122, Republic of Korea.
| |
Collapse
|
4
|
Kwag EB, Kim SD, Park JH, Park SJ, Jeong MK, Yoo HS. The Current Status of Integrative Oncology in Korea. Integr Cancer Ther 2021; 20:15347354211063809. [PMID: 34872372 PMCID: PMC8655452 DOI: 10.1177/15347354211063809] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Cancer is one of the leading causes of death worldwide, and Korea is no
exception. Humanity has been fighting cancer for many years, and as a result, we
now have effective treatments such as chemotherapy, radiation, and surgery.
However, there are other issues that we are only now beginning to address, such
as cancer patients’ quality of life. Moreover, numerous studies show that
addressing these issues holistically is critical for overall cancer treatment
and survival rates. This paper describes how Korea is attempting to reduce
cancer incidence and recurrence rates while also managing the quality of life of
cancer patients. Integrative Oncology is the field that addresses these broad
issues, and understanding the current state of integrative oncology in Korea is
critical. The goal of this paper is to provide an overview of the current state
of integrative oncology in Korea as well as to look ahead to future
developments.
Collapse
Affiliation(s)
- Eun-Bin Kwag
- Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea
| | - Soo-Dam Kim
- Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea
| | - Ji Hye Park
- Seoul Korean Medicine Hospital of Daejeon University, Seoul, Republic of Korea
| | - So-Jung Park
- Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea
| | - Mi-Kyung Jeong
- Korea Institute of Oriental Medicine, Daejeon, Republic of Korea
| | - Hwa-Seung Yoo
- Seoul Korean Medicine Hospital of Daejeon University, Seoul, Republic of Korea
| |
Collapse
|
5
|
Song SY, Chang HJ, Kim SD, Kwag EB, Park SJ, Yoo HS. Acute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs. Toxicol Rep 2021; 8:1819-1829. [PMID: 34804809 PMCID: PMC8590039 DOI: 10.1016/j.toxrep.2021.11.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 10/29/2021] [Accepted: 11/04/2021] [Indexed: 11/25/2022] Open
Abstract
HAD-B1 is used in Korean medicine to treat lung cancer patients. The acute and Sub-chronic toxicity of HAD-B1 was evaluated in Beagle dogs. No toxicologically significant effects were found. The NOAEL was ≥2000 mg/kg/day for both genders, with no target organ effect.
HAD-B1 is a herbal formula originated from Korean Traditional Medicine that used to treat lung cancer patients. Herein we assessed acute and sub-chronic toxicity of HAD-B1 in beagle dogs. Acute study, 4 weeks dose rate finding (DRF) study and sub chronic toxicity study for 13 weeks were done by oral administration at doses of 0, 500, 1000, and 2000 mg/kg. Neither oral acute toxicity study nor DRF study showed any significant clinical signs, death, or weight changes. Based on that, a sub-chronic study for 13-weeks was performed. As a result, HAD-B1 caused a decrease of mean daily feed consumption in females, infiltration of intestinal inflammatory cells in both sexes, a significant decrease in total cholesterol (TCHO) in females, Kupffer cell hypertrophy/hyperplasia in the liver as well as dilation of the sinusoid. However, there were no significant toxic effects in the treated group compared to the control group. Therefore, the No Observed Adverse Effect Level (NOAEL) of the HAD-B1 is at least 2000 mg/kg/day when administrated orally for 13 consecutive weeks. These results demonstrate that HAD-B1 consumption is relatively non-toxic and safe for clinical usage.
Collapse
Affiliation(s)
- Si-Yeon Song
- East West Cancer Center, Daejeon Korean Medicine Hospital, Daejeon University, 75, 176 Bun-Gil, Daedeok-daero, Seo-gu, Daejeon City, 35-235, Republic of Korea
| | - Hyeok-Joon Chang
- East West Cancer Center, Daejeon Korean Medicine Hospital, Daejeon University, 75, 176 Bun-Gil, Daedeok-daero, Seo-gu, Daejeon City, 35-235, Republic of Korea
| | - Soo-Dam Kim
- East West Cancer Center, Daejeon Korean Medicine Hospital, Daejeon University, 75, 176 Bun-Gil, Daedeok-daero, Seo-gu, Daejeon City, 35-235, Republic of Korea
| | - Eun-Bin Kwag
- East West Cancer Center, Daejeon Korean Medicine Hospital, Daejeon University, 75, 176 Bun-Gil, Daedeok-daero, Seo-gu, Daejeon City, 35-235, Republic of Korea
| | - So-Jung Park
- East West Cancer Center, Daejeon Korean Medicine Hospital, Daejeon University, 75, 176 Bun-Gil, Daedeok-daero, Seo-gu, Daejeon City, 35-235, Republic of Korea
| | - Hwa-Seung Yoo
- East West Cancer Center, Daejeon Korean Medicine Hospital, Daejeon University, 75, 176 Bun-Gil, Daedeok-daero, Seo-gu, Daejeon City, 35-235, Republic of Korea
| |
Collapse
|
6
|
Nonclinical Safety Pharmacology Study of the Herbal Product HAD-B1. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2021; 2021:2162986. [PMID: 34795778 PMCID: PMC8594988 DOI: 10.1155/2021/2162986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 10/20/2021] [Accepted: 10/22/2021] [Indexed: 12/24/2022]
Abstract
HAD-B1 is a Korean herbal formula designed to treat solid tumors, and through cell experiments, it has proven to have an anticancer effect. The current study aims to test the safety of HAD-B1. This experiment is under the regulation of ICH. In order to find if HAD-B1 has any effect on the CNS, 0, 500, 1000, and 2000 mg/kg/day of HAD-B1 were orally administered to male and female rats once. To discover any effect on the respiratory system, 0, 500, 1000, and 2000 mg/kg/day of HAD-B1 were orally given to male rats followed by measuring the respiratory rate, tidal volume, and minute respiratory volume. To assess the possibility of a delayed QT period as a result of the drug administration, hERG analysis was conducted at 0, 0.1, 0.3, and 1 μg/ml. To assess any effect on the cardiovascular system, 0, 500, 1000, and 2000 mg/kg/day of HAD-B1 were orally given to male beagle dogs once followed by temperature, blood pressure, ECG, and heart rate analyses. There were no clinically significant changes in both male and female rats on assessing any effects on the CNS. There were no clinically significant changes in male rats' respiratory assessment. There were no clinically significant changes in hERG analysis results. There were no clinically significant changes in the cardiovascular system of male beagle dogs. Our results demonstrate that HAD-B1 is a safe herbal formula that does not have a clinically significant effect on the CNS, respiratory, and cardiovascular systems.
Collapse
|